The immunological treatment of human marrow in vitro in transplantation biology

  • John G. Gribben
  • Lee M. Nadler
Part of the Cancer Treatment and Research book series (CTAR, volume 64)


Over the past decade, a greatly increased number of patients with advanced- stage hematologic and solid tumors have been treated with high-dose therapy and autologous bone marrow transplantation (ABMT) [1–10]. There are several potential advantages in using autologous over allogeneic transplantation. ABMT can be performed on patients with no histocompatible donor and can be performed on older patients, since there is no risk of graft- versus-host disease. However, the major obstacle to the use of ABMT is that the reinfusion of occult tumor cells in the autologous marrow will result in relapse of disease.


Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Lymphoma Cell Human Bone Marrow Autologous Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Armitage JO (1989). Bone marrow transplantation in the treatment of patients with lymphoma. Blood 73: 1749–1758.PubMedGoogle Scholar
  2. 2.
    Freedman AS, Takvorian T, Anderson KC, et al. (1990). Autologous bone marrow transplantation in B-cell non-Hodgkin’s lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 8: 1–8.Google Scholar
  3. 3.
    Philip T, Armitage JO, Spitzer G, et al. (1987). High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316: 1493–1498.PubMedCrossRefGoogle Scholar
  4. 4.
    Hurd DD, LeBien TW, Lasky LC, et al. (1988). Autologous bone marrow transplantation in non-Hodgkin’s lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med 85: 829–834.PubMedCrossRefGoogle Scholar
  5. 5.
    Gribben JG, Goldstone AH, Linch DC, et al. (1989). Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin’s lymphomas who are still responsive to conventional dose therapy. J Clin Oncol 7: 1621–1629.PubMedGoogle Scholar
  6. 6.
    Ball ED, Mills LE, Cornwell GG, et al. (1990). Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood 75: 1199–1206.PubMedGoogle Scholar
  7. 7.
    Gribben JG, Linch DC, Singer CRJ, McMillan AK, Jarrett M, Goldstone AH (1989). Successful treatment of refractory Hodgkin’s disease by high dose chemotherapy and autologous bone marrow transplantation. Blood 73: 340–344.PubMedGoogle Scholar
  8. 8.
    Wallerstein R, Spitzer G, Dunphy F, et al. (1990). A Phase II study of mitoxantrone, etoposide and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8: 1782–1788.PubMedGoogle Scholar
  9. 9.
    Frei E, Antman K, Teicher B, Schnipper L (1989). Bone marrow autotransplantation for solid tumors—prospects. J Clin Oncol 7: 515–526.PubMedGoogle Scholar
  10. 10.
    Peters WP, Shpall EJ, Jones RB (1988). High dose combination combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1501–1515.Google Scholar
  11. 11.
    Cleary ML, Chao J, Wanke R, Sklar J (1984). Immunoglobulin gene rearrangement as a diagnostic criterion of B cell lymphoma. Proc Natl Acad Sci USA 81: 593–597.PubMedCrossRefGoogle Scholar
  12. 12.
    Berliner N, Ault K, Martin P, Weisberg DS (1986). Detection of clonal excess in lymphoproliferative disease by kappa/lambda analysis: correlation with immunoglobulin gene DNA arrangements. Blood 67: 80–85.PubMedGoogle Scholar
  13. 13.
    Favrot M, Philip I, Combaret V, et al. (1989). Monoclonal antibodies and complement purged autograft in Burkitt lymphoma and lymphoblastic leukemia. Bone Marrow Transplant 4(1):202–204.PubMedGoogle Scholar
  14. 14.
    Sharp JG, Joshi SS, Armitage JO, et al. (1992). Significance of detection of occult non-Hodgkin’s lymphoma in histologically uninvolved bone marrow by culture technique. Blood 79: 1074–1080.PubMedGoogle Scholar
  15. 15.
    Estrov Z, Grunberger T, Dube ID (1986). Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med 315(9):538–542.PubMedCrossRefGoogle Scholar
  16. 16.
    Tsujimoto Y, Gorman J, Jaffe E, Croce CM (1985). The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390–1393.PubMedCrossRefGoogle Scholar
  17. 17.
    Bakshi A, Jensen JP, Goldman P, et al. (1985). Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899–906.CrossRefGoogle Scholar
  18. 18.
    Cleary ML, Sklar J (1985). Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 81: 593–597.CrossRefGoogle Scholar
  19. 19.
    Crescenzi M, Seto M, Herzig GP, Weiss PD, Griffith RC, Korsmeyer SJ (1988). Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 85(13):4869–4873.PubMedCrossRefGoogle Scholar
  20. 20.
    Ngan BY, Nourse J, Cleary ML (1989). Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 73(7): 1759–1762.PubMedGoogle Scholar
  21. 21.
    Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA (1987). Detection of minimal residual disease carrying the t(14;18) by DNA sequence amplification. Science 237: 175–178.PubMedCrossRefGoogle Scholar
  22. 22.
    Yunis JJ, Oken MM, Kaplan ME, Theologides RR, Howe A (1982). Distinctive chromosomal abnormalities in histological subtypes of non-Hodgkin’s lymphoma. N Engl J Med 307: 1231–1236.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiss LM, Warnke RA, Sklar J, Cleary ML (1987). Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317: 1185–1189.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee MS, Blick MB, Pathak S, et al. (1987). The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood 70(1):90–95.PubMedGoogle Scholar
  25. 25.
    Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ (1987). Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80(5): 1512–1515.PubMedCrossRefGoogle Scholar
  26. 26.
    Aisenberg AC, Wilkes BM, Jacobson JO (1987). The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 71(4):969–972.Google Scholar
  27. 27.
    Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G (1989). bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320(16):1047–1054.PubMedCrossRefGoogle Scholar
  28. 28.
    Gribben JG, Freedman AS, Woo SD, et al. (1991). All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78: 3275–3280.PubMedGoogle Scholar
  29. 29.
    Gribben JG, Freedman AS, Neuberg D, et al. (1991). Immunologie purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325(22):1525–1533.PubMedCrossRefGoogle Scholar
  30. 30.
    Freedman AS (1992). Cell surface markers in leukemia and lymphoma. In Blood Cell Biochemistry, Harris (ed). vol. 3, pp. 33–71.Google Scholar
  31. 31.
    Nadler LM, Takvorian T, Botnick L, et al. (1984). Anti-Bl monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet 2: 427–431.PubMedCrossRefGoogle Scholar
  32. 32.
    Sobol RE, Mick R, Royston I, et al. (1987). Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Eng J Med 316: 1111–1117.CrossRefGoogle Scholar
  33. 33.
    Freedman AS, Boyd AW, Berrebi A, et al. (1987). Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1: 9–15.PubMedGoogle Scholar
  34. 34.
    Reinherz EL, Nadler LM, Sallen SE, Schlossman SF (1979). Subset derivation of T-cell acute lymphoblastic leukemia in man. J Clin Invest 64: 392–397.PubMedCrossRefGoogle Scholar
  35. 35.
    Nadler LM, Reinherz EL, Weinstein HJ, D’Orsi CJ, Schlossman SF (1980). Heterogeneity of T cell lymphoblastic malignancies. Blood 55: 806–810.PubMedGoogle Scholar
  36. 36.
    Sheibani K, Nathwani BN, Winberg CD, et al. (1987). Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior. Cancer 60: 183–190.PubMedCrossRefGoogle Scholar
  37. 37.
    Sheibani K, Winberg CD, Van de Velde S, Blaney DW, Rappaport H (1987). Distribution of lymphocytes with IL-2 receptors (Tac antigen) in reactive lymphoproliferative processes, Hodgkin’s disease, and non-Hodgkin’s lymphoma. Am J Pathol 127: 27–37.PubMedGoogle Scholar
  38. 38.
    Weiss LM, Bindl JM, Picozzi VJ, Link MP, Warnke RA (1986). Lymphoblastic lymphoma: An immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood 67: 474–478.PubMedGoogle Scholar
  39. 39.
    Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM, Schlossman SF (1981). Expression of common acute lymphoblastic antigen (CALLA) by lymphomas of B cell and T cell lineage. Blood 58: 648–652.PubMedGoogle Scholar
  40. 40.
    Cossman J, Jaffe ES, Fisher RI (1984). Immunologie phenotypes of diffuse, aggressive, non-Hodgkin’s lymphomas: Correlations with clinical features. Cancer 54: 1310–1317.PubMedCrossRefGoogle Scholar
  41. 41.
    Doggett RS, Wood GS, Horning S, et al. (1984). The immunologie characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 115: 245–252.PubMedGoogle Scholar
  42. 42.
    Brouet JC, Rabian C, Gisselbrecht C, Flandrin G (1984). Clinical and immunological study of non-Hodgkin T cell lymphomas (cutaneous and lymphoblastic lymphomas excluded). Br J Haematol 57: 315–327.PubMedGoogle Scholar
  43. 43.
    Griffin JD, Mayer RJ, Weinstein HJ, et al. (1983). Surface marker analysis of acute myeloblastic leukemia: Identification of differentiation-associated phenotypes. Blood 62: 557–563.PubMedGoogle Scholar
  44. 44.
    San Miguel JF, Gonzales M, Canizo MC, et al. (1986). Surface markers analysis in AML and correlation with FAB classification. Br J Hematol 64: 547–560.CrossRefGoogle Scholar
  45. 45.
    Neame PB, Soamnoonsrup P, Browman GP, et al. (1986). Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood 1355–1362.Google Scholar
  46. 46.
    Griffin JD, Todd RF, Ritz J, et al. (1983). Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 61: 85–91.PubMedGoogle Scholar
  47. 47.
    Vrendenburgh JJ, Simpson W, Memoli VA, Ball ED (1991). Reactivity of anti-CD15 monoclonal antibody PM-81 with breast cancer and elimination of breast cancer cell lines from human bone marrow by PM-81 and immunomagnetic beads. Cancer Res 51: 2451–2455.Google Scholar
  48. 48.
    Vrendenburgh JJ, Ball ED (1990). Elimination of small cell carcinoma of the lung from human bone marrow by monoclonal antibodies and immunomagnetic beads. Cancer Res 50: 7216–7120.Google Scholar
  49. 49.
    Treleaven J, Gibson F, Udelstad J (1984). Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microsphere. Lancet ii: 70–76.CrossRefGoogle Scholar
  50. 50.
    Combaret V, Favrot MC, Chauvin F, Bouffet E, Philip I, Philip T (1989). Immunomagnetic depletion of malignant cells from autologous bone marrow graft: from experimental models to clinical trials. J Immunogenet 16(2): 125–136.PubMedCrossRefGoogle Scholar
  51. 51.
    Saleh RA, Gross S, Cassano W, Gee A (1988). Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer 62(11):2301–2303.PubMedCrossRefGoogle Scholar
  52. 52.
    Fialkow P, Jacobson RJ, Papayannopolou T (1977). Chronic myelogenous leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/ macrophage. Am J Med 63: 125–129.PubMedCrossRefGoogle Scholar
  53. 53.
    Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal LM (1978). Chronic myelogenous leukemia: origin of some lymphocytes from leukemia stem cells. J Clin Invest 62: 815–821.PubMedCrossRefGoogle Scholar
  54. 54.
    Martin PJ, Najfeld V, Hansen JA, Penfold GK, Jacobson RJ, Fialkow PJ (1980). Involvement of the B-lymphoid system in chronic myelogenous leukemia. Nature 287: 49–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Bernstein ID, Singer JW, Smith FO, et al. (1992). Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 79: 1811–1816.PubMedGoogle Scholar
  56. 56.
    Caligaris-Cappio F, Bergui L, Tesio L, et al. (1985). Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 76: 1243–1251.PubMedCrossRefGoogle Scholar
  57. 57.
    Bertoli LF, Kubagawa H, Borzillo GV, et al. (1988). Bone marrow origin of a B-cell lymphoma. Blood 72: 94–101.PubMedGoogle Scholar
  58. 58.
    Roy DC, Felix M, Cannady WG, Cannistra S, Ritz J (1990). Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk Res 14: 407–416.PubMedCrossRefGoogle Scholar
  59. 59.
    Trickett AE, Ford DJ, Lam-Po-Tang PRL, Vowels MR (1991). Immunomagnetic bone marrow purging of common acute lymphoblastic leukemia cells: suitability of BioMag particles. Bone Marrow Transplant 7: 199–203.PubMedGoogle Scholar
  60. 60.
    De Fabritiis P, Bregni M, Lipton J, et al. (1985). Elimination of clonogenic Burkitt’s lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 65: 1064–1070.PubMedGoogle Scholar
  61. 61.
    Bast RC, De Fabritiis P, Lipton J, et al. (1985). Elimination of malignant clonogenic cells from human bone marrows using multiple monoclonal antibodies and complement. Cancer Res 45: 499–503.PubMedGoogle Scholar
  62. 62.
    LeBien TW, Stepan DE, Bartholomew RM, Strong RC, Anderson JM (1985). Utilization of a colony assay to assess the variables influencing elimination of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood 65: 945–950.Google Scholar
  63. 63.
    Negrin RS, Kiem HP, Schmidt-Wolf IGH, Blume KG, Cleary M (1991). Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 77: 654–660.PubMedGoogle Scholar
  64. 64.
    Schlager SI, Ohanian SH, Borsos T (1978). Identification of lipids associated with the ability of tumor cells to resist humoral immune attack. J Immunol 120: 472–480.PubMedGoogle Scholar
  65. 65.
    Schlager SI, Boyle MDP, Ohanian SH, Borsos T (1977). Effect of inhibiting DNA, RNA and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. Cancer Res 37: 1432–1437.PubMedGoogle Scholar
  66. 66.
    Gee AP, Boyle MDP (1988). Purging tumor cells from bone marrows by use of antibody and complement: a critical appraisal. J Natl Cancer Inst 80: 154–159.PubMedCrossRefGoogle Scholar
  67. 67.
    Gee AP, Bruce KM, Morris TD, Boyle MD (1985). Evidence for an anticomplementary factor associated with human bone marrow cells. J Natl Cancer Inst 75(3):441–445.PubMedGoogle Scholar
  68. 68.
    Bast RC, Ritz J, Lipton LM, et al. (1983). Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43: 1389–1394.PubMedGoogle Scholar
  69. 69.
    Howell AL, Fogg LM, Davis BH, Ball ED (1989). Continuous infusion of complement by an automated cell processor enhances cytotoxicity of monoclonal antibody sensitized leukemia cells. Bone Marrow Transplant 4(3):317–322.PubMedGoogle Scholar
  70. 70.
    Humblet Y, Feyens AM, Sekhavat M, Agaliotis D, Canon JL, Symann ML (1989). Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts. Cancer Res 49(18):5058–5061.PubMedGoogle Scholar
  71. 71.
    Aihara M, Aihara Y, Schmidt-Wolf G, et al. (1991). A combined approach for purging multidrug-resistance leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. Blood 77: 2079–2084.PubMedGoogle Scholar
  72. 72.
    De Fabritiis P, Ferrero D, Sandrelli A, et al. (1989). Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. Bone Marrow Transplant 4(6).669–674.PubMedGoogle Scholar
  73. 73.
    Simonsson B, Burnett AK, Prentice HG, et al. (1989). Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 3(9):631–636.PubMedGoogle Scholar
  74. 74.
    Kvalheim G, Sorensen O, Fodstad O, et al. (1988). Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 3: 31–41.PubMedGoogle Scholar
  75. 75.
    Rhodes EG, Baker P, Rhodes JM, Davies JM, Cawley JC (1991). Peanut agglutinin in combination with CD 19 monoclonal antibody has potential as a purging agent in myeloma. Exp Hematol 19: 833–837.PubMedGoogle Scholar
  76. 76.
    Gribben JG, Saporito L, Barber M, et al. (1992). Bone marrows of non-Hodgkin’s lymphoma patients with a bcl-2 translocation can be purged of PCR detectable lymphoma cells using monoclonal antibodies and immunomagnetic beads. Blood 80: 1083–1089.PubMedGoogle Scholar
  77. 77.
    Elias AD, Pap SA, Bernai SD (1990). Purging of small cell lung cancer-contaminated bone marrow by monoclonal antibodies and magnetic beads. Prog Clin Biol Res 333(1):263–275.PubMedGoogle Scholar
  78. 78.
    Schpall EJ, Bast RC, Joines WT, et al. (1991). Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7: 145–151.Google Scholar
  79. 79.
    Philip T, Bernard JL, Zucker JM, et al. (1987). High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J Clin Oncol 5(2):266–271.PubMedGoogle Scholar
  80. 80.
    Kemshead JT, Treleaven J, Heath L, Meara AO, Gee A, Ugelstad J (1987). Monoclonal antibodies and magnetic microspheres for the depletion of leukemic cells from bone marrow harvested for autologous transplantation. Bone Marrow Transplant 2: 133–139.PubMedGoogle Scholar
  81. 81.
    FitzGerald DJ, Willingham MC, Cardarelli CO, et al. (1987). A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84(12):4288–4892.PubMedCrossRefGoogle Scholar
  82. 82.
    Grossbard ML, Nadler LM (1992). Immunotoxin Therapy of Malignancy. In Important Advances in Oncology, DeVita VT, Hellamn S, Rosenberg SA (ed). Philadelphia: J.B. Lippincott, pp. 111–135.Google Scholar
  83. 83.
    Strong RC, Uckun F, Youle RJ, Kersey J, Vallera DA (1985). Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 66: 627–635.Google Scholar
  84. 84.
    Montgomery RB, Kurtzberg J, Rhinehardt-Clark A, et al. (1990). Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2′-deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 5: 395–402.PubMedGoogle Scholar
  85. 85.
    Preijers FWMB, De Witte T, Wessels JMC, et al. (1989). Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WTl-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 74: 1152–1158.PubMedGoogle Scholar
  86. 86.
    Uckun F, Kersey JH, Vallera DA, et al. (1990). Autologous bone marrow transplantation in high risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 76: 1723–1733.PubMedGoogle Scholar
  87. 87.
    Berenson RJ, Andrews RG, Bensinger WI, et al. (1988). Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 81: 951–955.PubMedCrossRefGoogle Scholar
  88. 88.
    Berenson RJ, Bensinger WI, Hill RS, et al. (1991). Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 77: 1717–1722.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • John G. Gribben
  • Lee M. Nadler

There are no affiliations available

Personalised recommendations